Generation Investment Management LLP Has $592.42 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Generation Investment Management LLP has reduced its stake in Thermo Fisher Scientific by 24.3%, owning 1,190,561 shares after the sale of 381,173 shares in the first quarter.
• Insider selling activity included EVP Gianluca Pettiti selling 400 shares for $191,992 and CEO Marc N. Casper selling 10,000 shares for $5,009,600, representing decreases in their respective holdings.
• Wall Street analysts are optimistic, with a consensus rating of "Moderate Buy" and an average target price of $593.00 for the stock.

Generation Investment Management LLP lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 24.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,190,561 shares of the medical research company's stock after selling 381,173 shares during the quarter. Thermo Fisher Scientific makes up about 3.6% of Generation Investment Management LLP's holdings, making the stock its 12th biggest holding. Generation Investment Management LLP owned 0.32% of Thermo Fisher Scientific worth $592,423,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in TMO. GAMMA Investing LLC lifted its position in shares of Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $532,360,000. Farallon Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 73.8% during the 4th quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock valued at $641,577,000 after buying an additional 523,800 shares during the period. Sarasin & Partners LLP acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $242,991,000. Finally, Two Sigma Advisers LP boosted its stake in shares of Thermo Fisher Scientific by 81.6% during the 4th quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock valued at $485,479,000 after buying an additional 419,200 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO traded up $4.94 during trading on Thursday, hitting $489.49. The stock had a trading volume of 1,404,235 shares, compared to its average volume of 1,629,226. The firm has a market cap of $184.84 billion, a PE ratio of 28.31, a P/E/G ratio of 2.59 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a 50 day simple moving average of $459.03 and a 200-day simple moving average of $453.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on TMO shares. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Barclays lifted their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. HSBC restated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $589.38.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,666 shares of company stock worth $13,982,763 in the last quarter. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.